F5, Inc. (FFIV) Cybersecurity Incident-Related Securities Class Action Pending As Adverse Financial Impact Clarified – Hagens Berman

A securities class action lawsuit, filed in the wake of an announcement by F5, Inc. (NASDAQ: FFIV) that it experienced a “material cybersecurity incident,” which it discovered on August 9, 2025, seeks to represent investors who purchased F5 securities between October 28, 2024 and October 27, 2025. The lawsuit follows F5’s October 15 and 27, […]

Coupang, Inc. (CPNG) Class Period Expanded in Pending Investor Securities Lawsuit – Hagens Berman

National shareholder rights firm Hagens Berman is notifying investors in Coupang, Inc. (NYSE: CPNG) that a second securities class action has been filed expanding the Class Period and seeks to represent investors who purchased Coupang securities between May 7, 2025 and December 16, 2025. The Lead Plaintiff Deadline remains February 17, 2026. The firm is

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Gauzy

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gauzy To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gauzy between March 11, 2025 and November 13, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Quebec Rare Earth Elements Acquires Moose REE Project in Quebec, Canada

Toronto, Ontario–(Newsfile Corp. – January 12, 2026) – Quebec Rare Earth Elements Corp. (CSE: QREE) (the “Company“) is pleased to announce that it has entered into an option agreement to acquire the Moose REE Project, a 7km diameter circular magnetic anomaly with a central magnetic core of 2 km in diameter (Exhibit 1). Although minimal

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia–(Newsfile Corp. – January 12, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company“), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the “Offering“), issuing 3,322,153 units (each, a “Unit“) at

18 Greenberg Traurig Attorneys Named to Denver’s Top Lawyers 2026 List

Eighteen attorneys from global law firm Greenberg Traurig, LLP have been named to 5280 magazine’s Denver’s Top Lawyers 2026 list, which recognizes the best attorneys in the Mile High City and beyond. 5280 magazine creates annual lists across various industries as resources for businesses and individuals in the Mile High City to find professionals with

Persistent Corneal Edema Market to Show Impressive Growth at a CAGR of 21.8% During the Forecast Period (2025-2034) | DelveInsight

The persistent corneal edema market is experiencing steady growth, driven by rising clinical awareness, improved postoperative monitoring, and growing focus on endothelial dysfunction-related complications. Additionally, the launch of emerging therapies such as AURN001 (Aurion Biotech/Alcon), EO2002 (Emmecell), TTHX1114 (Trefoil Therapeutics), and others will further drive the market forward. DelveInsight’s Persistent Corneal Edema Market Insights report

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. – ZBIO

NEW YORK CITY, NY / ACCESS Newswire / January 12, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zenas and certain of its officers and/or

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into pregnancy health. Nuvo Intl Group Inc, a leader in remote pregnancy monitoring and AI-enabled maternal-fetal care, today unveiled its pregnancy data solution built from real-world use of its FDA-cleared INVU(TM) pregnancy monitoring wearable technology. Through INVU(TM), Nuvo has assembled what

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. – ORGO

NEW YORK CITY, NY / ACCESS Newswire / January 12, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ:ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Organogenesis and certain of its officers and/or

Scroll to Top